SEC Filing Summary: Renovaro Biosciences Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Renovaro Biosciences Inc. (not Lunai Bioworks Inc.) on December 1, 2023. The registrant is a Delaware corporation with its principal executive offices in Los Angeles, California. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol RENB.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the release of an investor presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is procedural, intended to satisfy Regulation FD disclosure requirements regarding the release of non-public information via an investor presentation.
Guidance, Outlook, and Risks
The company made an investor presentation available on its website on December 1, 2023, which is furnished as Exhibit 99.1. The filing explicitly states that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K form itself.
Key Facts for Investor Verification
- Verify the company name is Renovaro Biosciences Inc., as the input metadata incorrectly referenced "Lunai Bioworks Inc."
- Review Exhibit 99.1 (Investor Presentation) for actual business updates, as the 8-K text only announces its availability.
- Note that the presentation content is not legally "filed" with the SEC and is not incorporated by reference into other filings unless expressly stated.
- Confirm the trading symbol is RENB on the Nasdaq.